PROCEPT BioRobotics Corp. Insider Deals: EVP Nouri Alaleh Sells 3,098 Shares as Stock Slides 12.8% Monthly – What It Means for Investors

Insider Selling Amid a Slipping Stock

The latest Form 4 from Nouri Alaleh, EVP, CLO and Chief Corporate Secretary, shows a modest block of 3,098 common shares sold on 10 March 2026. The sale was executed under a Rule 10b‑5‑1 trading plan adopted last June, with a weighted average price of $25.60, just below the current market price of $26.12. Alaleh’s post‑transaction holdings fall to 111,166 shares—roughly 8 % of the outstanding shares—after a series of buy and sell trades in the preceding days.

What This Means for Investors

Alaleh’s selling pattern—periodic divestitures of 2,000‑5,000 shares interspersed with larger purchases—has been consistent since early 2025. The most recent sale, while modest, occurs at a time when PROCEPT’s share price has been under pressure: a 12.8 % monthly decline, a 54.7 % yearly slide, and a 52‑week low of $19.35. The market’s reaction to insider selling has been muted: sentiment remains positive (+4) and social‑media buzz is moderate (10.9 %). For investors, the takeaway is that Alaleh’s trades appear to be part of a pre‑planned execution schedule rather than a sign of panic or impending collapse. Nonetheless, the cumulative effect of insider selling in the face of a weakening business outlook (notably the adjusted EBITDA loss and revenue guidance revision) could amplify volatility, especially if additional blocks surface.

Alaleh’s Transaction Profile

Alaleh’s insider history is dominated by Rule 10b‑5‑1 plans and RSU vesting events. In March 2026 she bought 43,811 shares at $0.00 (a stock option exercise) and sold 6,892 shares at $23.70 earlier that week. Her most recent purchase on 5 March was also at $0.00, again reflecting an option exercise, while her March 10 sale is priced just below market. Over the last 18 months she has traded roughly 300,000 shares, maintaining a net holding that fluctuates between 70,000 and 120,000 shares. This pattern suggests a disciplined approach: she buys when options vest or when she intends to build a long‑term position, and sells only when the plan requires or when the market price aligns with her target. There is no evidence of “inside‑information” trading; instead, her trades align with the company’s vesting and plan schedules.

Broader Insider Activity

While Alaleh’s block is relatively small, the broader insider landscape is crowded. CEO Larry Wood has recently purchased 182,392 shares, and CFO Kevin Waters has sold 6,721 shares at $23.70. The most active buyer, Desai Antal Rohit, has added over 400,000 shares in a series of purchases in March. This mix of buying and selling across the top ranks suggests that insiders are not all on the same side of the market, hinting at differing views on the company’s trajectory.

Outlook for PROCEPT

PROCEPT operates in a niche market—autonomous tissue removal for benign prostatic hyperplasia—and faces regulatory scrutiny (Bronstein, Gewirtz & Grossman are investigating potential securities claims). The recent quarterly results, coupled with a downward revision of 2026 revenue guidance, have eroded investor confidence. Insider activity will likely continue to be monitored closely; a sharp rise in selling volume could serve as a warning signal for a further decline, whereas sustained buying—particularly by senior executives—may temper panic and reinforce long‑term support. For investors, the current environment demands a careful assessment of both the company’s fundamental challenges and the strategic intent behind insider trades.